ONCOLOGY INSTITUTE INC/THE (TOI) Fundamental Analysis & Valuation

NASDAQ:TOI • US68236X1000

Current stock price

3.52 USD
-0.02 (-0.56%)
At close:
3.5817 USD
+0.06 (+1.75%)
Pre-Market:

This TOI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. TOI Profitability Analysis

1.1 Basic Checks

  • In the past year TOI has reported negative net income.
  • In the past year TOI has reported a negative cash flow from operations.
  • TOI had negative earnings in 4 of the past 5 years.
  • TOI had a negative operating cash flow in each of the past 5 years.
TOI Yearly Net Income VS EBIT VS OCF VS FCFTOI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M

1.2 Ratios

  • TOI's Return On Assets of -30.53% is on the low side compared to the rest of the industry. TOI is outperformed by 83.00% of its industry peers.
Industry RankSector Rank
ROA -30.53%
ROE N/A
ROIC N/A
ROA(3y)-31.23%
ROA(5y)-19.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TOI Yearly ROA, ROE, ROICTOI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K

1.3 Margins

  • The Gross Margin of TOI (15.20%) is worse than 63.00% of its industry peers.
  • TOI's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for TOI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 15.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.68%
GM growth 5Y-5.03%
TOI Yearly Profit, Operating, Gross MarginsTOI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 -20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. TOI Health Analysis

2.1 Basic Checks

  • TOI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for TOI has been increased compared to 1 year ago.
  • The number of shares outstanding for TOI has been increased compared to 5 years ago.
  • TOI has a better debt/assets ratio than last year.
TOI Yearly Shares OutstandingTOI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
TOI Yearly Total Debt VS Total AssetsTOI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • TOI has an Altman-Z score of 1.48. This is a bad value and indicates that TOI is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.48, TOI is doing worse than 61.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 1.48
ROIC/WACCN/A
WACC8.53%
TOI Yearly LT Debt VS Equity VS FCFTOI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • TOI has a Current Ratio of 1.59. This is a normal value and indicates that TOI is financially healthy and should not expect problems in meeting its short term obligations.
  • TOI's Current ratio of 1.59 is fine compared to the rest of the industry. TOI outperforms 63.00% of its industry peers.
  • TOI has a Quick Ratio of 1.35. This is a normal value and indicates that TOI is financially healthy and should not expect problems in meeting its short term obligations.
  • TOI has a Quick ratio of 1.35. This is comparable to the rest of the industry: TOI outperforms 57.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.59
Quick Ratio 1.35
TOI Yearly Current Assets VS Current LiabilitesTOI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. TOI Growth Analysis

3.1 Past

  • TOI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.34%, which is quite impressive.
  • TOI shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.79%.
  • The Revenue has been growing by 21.81% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)20.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.77%
Revenue 1Y (TTM)27.79%
Revenue growth 3Y25.8%
Revenue growth 5Y21.81%
Sales Q2Q%41.58%

3.2 Future

  • Based on estimates for the next years, TOI will show a very strong growth in Earnings Per Share. The EPS will grow by 35.82% on average per year.
  • Based on estimates for the next years, TOI will show a very strong growth in Revenue. The Revenue will grow by 27.58% on average per year.
EPS Next Y45.62%
EPS Next 2Y35.82%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year29.42%
Revenue Next 2Y27.58%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TOI Yearly Revenue VS EstimatesTOI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
TOI Yearly EPS VS EstimatesTOI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

1

4. TOI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TOI. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TOI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TOI Price Earnings VS Forward Price EarningsTOI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TOI Per share dataTOI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4 5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as TOI's earnings are expected to grow with 35.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.82%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TOI Dividend Analysis

5.1 Amount

  • No dividends for TOI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TOI Fundamentals: All Metrics, Ratios and Statistics

ONCOLOGY INSTITUTE INC/THE

NASDAQ:TOI (4/20/2026, 8:00:01 PM)

Premarket: 3.5817 +0.06 (+1.75%)

3.52

-0.02 (-0.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-12
Earnings (Next)05-13
Inst Owners44.77%
Inst Owner Change0%
Ins Owners15.14%
Ins Owner Change-8.94%
Market Cap347.92M
Revenue(TTM)502.73M
Net Income(TTM)-50.26M
Analysts82.5
Price Target7.14 (102.84%)
Short Float %10.6%
Short Ratio4.19
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.84%
Min EPS beat(2)-22.31%
Max EPS beat(2)33.99%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.41%
Min Revenue beat(2)0.56%
Max Revenue beat(2)10.26%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.69%
PT rev (3m)7.69%
EPS NQ rev (1m)11.43%
EPS NQ rev (3m)13.89%
EPS NY rev (1m)5.88%
EPS NY rev (3m)9.68%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.69
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.52
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS5.09
BVpS-0.16
TBVpS-0.34
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -30.53%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 15.2%
FCFM N/A
ROA(3y)-31.23%
ROA(5y)-19.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.68%
GM growth 5Y-5.03%
F-Score5
Asset Turnover3.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.08%
Cap/Sales 0.64%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.59
Quick Ratio 1.35
Altman-Z 1.48
F-Score5
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)61.37%
Cap/Depr(5y)80.17%
Cap/Sales(3y)1%
Cap/Sales(5y)1.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.77%
EPS Next Y45.62%
EPS Next 2Y35.82%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)27.79%
Revenue growth 3Y25.8%
Revenue growth 5Y21.81%
Sales Q2Q%41.58%
Revenue Next Year29.42%
Revenue Next 2Y27.58%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y39.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year113.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.35%
OCF growth 3YN/A
OCF growth 5YN/A

ONCOLOGY INSTITUTE INC/THE / TOI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ONCOLOGY INSTITUTE INC/THE?

ChartMill assigns a fundamental rating of 2 / 10 to TOI.


Can you provide the valuation status for ONCOLOGY INSTITUTE INC/THE?

ChartMill assigns a valuation rating of 1 / 10 to ONCOLOGY INSTITUTE INC/THE (TOI). This can be considered as Overvalued.


Can you provide the profitability details for ONCOLOGY INSTITUTE INC/THE?

ONCOLOGY INSTITUTE INC/THE (TOI) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ONCOLOGY INSTITUTE INC/THE?

The Earnings per Share (EPS) of ONCOLOGY INSTITUTE INC/THE (TOI) is expected to grow by 45.62% in the next year.